HilleVax (HLVX) Stock Price, News & Analysis

Company Overview

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $2.09 to $2.16
• 50-Day Range: $1.83 to $2.17
• 52-Week Range: $1.34 to $2.17
• Volume: 162,970 shs
• Average Volume: 356,537 shs
• Market Capitalization: $107.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Hold

HilleVax Stock Analysis - MarketRank™

HilleVax scored higher than 40% of companies evaluated by MarketBeat, and ranked 710th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

HilleVax has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

HilleVax has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for HilleVax are expected to grow in the coming year, from ($2.64) to ($1.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of HilleVax is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of HilleVax is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

HilleVax has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.33% of the float of HilleVax has been sold short.

Short Interest Ratio / Days to Cover

HilleVax has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HilleVax has recently decreased by 53.28%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HilleVax does not currently pay a dividend.

Dividend Growth

HilleVax does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.33% of the float of HilleVax has been sold short.

Short Interest Ratio / Days to Cover

HilleVax has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HilleVax has recently decreased by 53.28%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

HilleVax has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for HilleVax this week, compared to 1 article on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, HilleVax insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.90% of the stock of HilleVax is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.42% of the stock of HilleVax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HLVX Stock Analysis - Frequently Asked Questions

How have HLVX shares performed this year?

HilleVax's stock was trading at $2.07 at the start of the year. Since then, HLVX shares have increased by 3.9% and is now trading at $2.15.

How were HilleVax's earnings last quarter?

HilleVax, Inc. (NASDAQ:HLVX) released its quarterly earnings data on Thursday, May, 8th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.25.

When did HilleVax IPO?

HilleVax (HLVX) raised $200 million in an IPO on Friday, April 29th 2022. The company issued 11,765,000 shares at $16.00-$18.00 per share.

How do I buy shares of HilleVax?

Shares of HLVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of HilleVax own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HilleVax investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Home Depot (HD).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/26/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HLVX
• CIK: 1888012
• Web: www.hillevax.com
• Phone: 617-213-5054
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for HilleVax: $2.00
• High Price Target: $2.00
• Low Price Target: $2.00
• Potential Upside/Downside: -7.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$147.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -51.86%
• Return on Assets: -41.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 25.32
• Quick Ratio: 25.32

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.10 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 50,140,000
• Free Float: 37,656,000
• Market Cap: $107.80 million
• Optionable: Not Optionable
• Beta: 0.76